Scandion Oncology
Denmark - CopenhagenBiotechnology
Focus: Scandion Oncology is a Danish biotech company focused on R&D and clinical trials targeting chemotherapy resistance in oncology and neurology indications. The company operates as a public-stage enterprise with a lean, innovation-focused pipeline.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
0
About Scandion Oncology
AI assessmentNot HiringNo open roles listed right now. Follow Scandion Oncology to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
FOLFIRI Protocol
Metastatic Colorectal CancerClinical Trials (1)
NCT04247256A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI
Phase 1/2Help build intelligence for Scandion Oncology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.